Liraglutide Doesn't Affect Gastric Emptying in Type 1 Diabetes

Share this content:
Liraglutide Doesn't Affect Gastric Emptying in Type 1 Diabetes
Liraglutide Doesn't Affect Gastric Emptying in Type 1 Diabetes

MONDAY, Nov. 28, 2016 (HealthDay News) -- For individuals with type 1 diabetes mellitus (T1DM), liraglutide therapy does not affect the rate of gastric emptying (GE) during hypoglycemia, according to a study published online Nov. 21 in Diabetes, Obesity and Metabolism.

Christian Seerup Frandsen, M.D., from the University of Copenhagen in Denmark, and colleagues examined the effect of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide on counterregulatory responses and GE rate during hypoglycemia in individuals with T1DM in a 12-week randomized trial. Twenty patients aged older than 18 years and with glycated hemoglobin ≥8 percent were randomized to liraglutide once daily or placebo as add-on to insulin treatment. A hypoglycemic clamp was carried out followed by a liquid meal before and at the end of treatment.

The researchers observed no significant between-group differences in the changes in GE rates after 12 weeks of treatment (P = 0.96); no significant changes were seen from baseline whether assessed by area under the acetaminophen curve or time to peak. Similar between-group results were seen in secondary end points, including glycemic recovery, counterregulatory hormone responses, systolic blood pressure, and GLP-1 and pancreatic polypeptide responses. There was an increase in heart rate with liraglutide (69 ± 4 to 80 ± 5 beats/min; P = 0.02).

"Liraglutide does not compromise glycemic recovery, GE rate, or counterregulatory hormone responses in type 1 diabetes during hypoglycemia," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »